Bio-Rad Laboratories, Inc.Class A
BIO
Key stats
- Open
- 382.88
- Day high
- 390.00
- Day low
- 369.40
- Previous close
- 386.00
- Volume
- 182.3K
- VWAP
- 372.97
- 52-week high
- 396.23
- 52-week low
- 236.73
- Market cap
- 10.38B
- Shares out
- 21.83M
- Employees
- 7,450
- Listed
- 1980
About Bio-Rad Laboratories, Inc.Class A
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
LABORATORY ANALYTICAL INSTRUMENTS · HERCULES, CA · bio-rad.com
Options · expiring Nov 20
Nov 12, 4:00 PM ET- Call open interest
- 18
- Put open interest
- 217
- Put/call
- 12.06
- At-the-money IV
- 47.7%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 330 put | 5.52 | Nov 3, 1:11 PM | 70 | 70 | 53.4% |
| 320 put | 4.83 | Oct 14, 3:31 PM | 8 | 0 | 68.3% |
| 370 put | 5.07 | Nov 10, 9:41 AM | 5 | 75 | 34.7% |
| 380 put | 15.00 | Oct 29, 11:41 AM | 4 | 4 | 30.2% |
| 390 call | 13.80 | Nov 4, 2:16 PM | 3 | 13 | 51.4% |
| 360 call | 31.96 | Oct 27, 11:58 AM | 2 | 0 | 43.3% |
Quarterly results
Massive · Nov 4, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $656.40M | $651.00M | $592.10M | $693.20M |
| Gross profit | $328.60M | $345.80M | $309.40M | $345.20M |
| Operating income | −$49.70M | $72.60M | $34.10M | $53.90M |
| Net income | $458.60M | $371.40M | −$527.10M | $720.00M |
| Diluted EPS | 17.02 | 13.85 | -19.55 | 26.65 |
| Operating cash flow | $96.40M | $98.70M | $108.10M | $164.90M |
| Assets | $10.78B | $10.25B | $9.79B | $10.58B |
| Liabilities | $3.18B | $3.08B | $2.94B | $3.12B |
| Equity | $7.60B | $7.17B | $6.85B | $7.45B |
Technicals
Massive · Nov 12, 2026- 50-day average373.38
- 200-day average316.63
- RSI (14 days)47.7
Short interest
Massive · Oct 30, 2026- Oct 30, 20261.16M shares · 5.1 days to cover
- Oct 15, 20261.10M shares · 4.8 days to cover
- Sep 30, 20261.18M shares · 4.3 days to cover
- Sep 15, 2026998.7K shares · 3.8 days to cover
Related companies
MassiveNews coverage
No stories about Bio-Rad Laboratories, Inc.Class A right now.